Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes.

Annals of hematology - 1 Dec 2022

Mathieu Meunier, Friedrich Chloé, Ducrot Nicolas, Zannoni Johanna, Sylvie Tondeur, Jerraya Nelly, Rousseaux Sophie, Chuffart Florent, Kosmider Olivier, Karim Zoubida, Park Sophie

Abstract excerpt

In low-risk myelodysplastic syndrome (LR-MDS), erythropoietin (EPO) is widely used for the treatment of chronic anemia. However, initial response to EPO has time-limited effects. Luspatercept reduces red blood cell transfusion dependence in LR-MDS patients. Here, we investigated the molecular action of luspatercept (RAP-536) in an in vitro model of erythroid differentiation of MDS, and also in a in vivo PDX...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mice
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myelodysplastic Syndromes

Share to Oxidative Stress

Source

Identifiers

PMID: 36195681
DOI: 10.1007/s00277-022-04993-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes.PMID 36195681Read ↗

Genetic iron overload aggravates, and pharmacological iron restriction improves, MDS pathophysiology in a preclinical studySemantic proximity Read ↗

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.Semantic proximity Read ↗

Research progress on ferroptosis in Myelodysplastic syndromesSemantic proximity Read ↗

Therapy for lower-risk MDS.Semantic proximity Read ↗

Smad2/3‐pathway ligand trap luspatercept enhances erythroid differentiation in murine β‐thalassaemia by increasing GATA‐1 availabilitySemantic proximity Read ↗

Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS.Semantic proximity Read ↗

Construction and experimental validation of a novel ferroptosis‐related gene signature for myelodysplastic syndromesSemantic proximity Read ↗

Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromesSemantic proximity Read ↗

Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".Semantic proximity Read ↗

ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.Semantic proximity Read ↗

Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy.Semantic proximity Read ↗

ASXL1 Mutations with Serum EPO Levels Predict a Poor Response to Darbepoetin Alfa in Lower-Risk MDS: W-JHS MDS01 TrialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.